Acer Therapeutics Inc

NASDAQ:ACER   10:08:51 AM EDT
2.09
-0.10 (-4.57%)
Products

Acer Therapeutics Announces Agreement With FDA On Special Protocol Assessment For Its Phase 3 EDSIVO™ (Celiprolol) Trial In Vascular Ehlers-Danlos Syndrome Patients

Published: 05/09/2022 13:49 GMT
Acer Therapeutics Inc (ACER) - Acer Therapeutics Announces Agreement With FDA on Special Protocol Assessment for Its Phase 3 Edsivo™ (celiprolol) Trial in Vascular Ehlers-danlos Syndrome Patients.
Acer Therapeutics Announces Agreement With FDA on Special Protocol Assessment for Its Phase 3 Edsivo™ (celiprolol) Trial in Vascular Ehlers-danlos Syndrome Patients.
Acer Therapeutics Inc - Duration of Discover Trial is Currently Estimated to Be Approximately 3.5 Years to Completion.